KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family

WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025.

The 3P Small-Mini System is a versatile plate and screw solution featuring variable-angle locking implants designed specifically for pediatric orthopedic surgeons. It supports a wide range of trauma and deformity surgeries with procedure-specific and utility plates in sizes 2.0mm, 2.4mm, 2.7mm, and 3.5mm. Featuring specialized instruments, streamlined tray layouts, and color-coding for enhanced surgical flow, the system aims to optimize operating room efficiency. As the second release in the 3P Pediatric Plating Platform, it follows the highly successful 3P Hip System.

OrthoPediatrics President of Trauma, Deformity Correction and OPSB, Joe Hauser commented, “This milestone represents another significant step forward in the 3P product development journey. Our engineering and surgeon design teams continue to demonstrate exceptional work in advancing the next 3P system following the successful launch of 3P Hip. This innovative platform is redefining how pediatric surgeons treat their patients, addressing a significant unmet medical need, and we are excited to move toward a limited market release in early 2026.”

CEO, David Bailey echoed those comments, saying “We remain focused on delivering a comprehensive portfolio of innovative orthopedic solutions to expand our support to more pediatric patients. This is the 6th FDA approval for the company in 2025, and was received ahead of our expectations, thanks to the dedication and excellence of our R&D team. I’m incredibly proud of their work and look forward to continuing to develop not only the 3P platform but our larger portfolio with even more groundbreaking products in the near future.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit .

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937- 5406



EN
28/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Business Highlights       Helped over 37,000 children in the third quarter of 2025 and approximat...

 PRESS RELEASE

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating ...

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025. The 3P Small-Mini System is a versatile plate and s...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Third Quarter Financial Results on Oct...

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference ...

 PRESS RELEASE

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue...

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025 financial guidance. Preliminary Third Quarter 2025 Results...

 PRESS RELEASE

OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spin...

OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”). Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky who, along with Dr. Kent Wa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch